Casopitant


Casopitant, Zunrisa ) is a neurokinin 1 receptor antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting. It is currently under development by GlaxoSmithKline.
In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.